AstraZeneca dishes on its $500M new home in Cambridge, U.K.

AstraZeneca's ($AZN) sweeping new Cambridge, U.K., campus will be constructed with collaboration in mind, the company said, unveiling plans for the $500 million site it aims to open in 2016. The pharma giant is in the process of ditching its far-flung R&D operations around the globe and consolidating into a single headquarters in one of its home country's most vibrant hubs for biomedical research. The new site, which will sit on the Cambridge Biomedical Campus, is designed to unite AstraZeneca's small-molecule and biologics development teams, employing open workspaces to facilitate the sharing of ideas between employees and external collaborators, the company said. Release | Renderings

Suggested Articles

In this week's EuroBiotech Report, Sitryx inks Lilly deal, Genfit downplays COVID-19 impact on NASH data and Gilead tests remdesivir in U.K.

Amgen and new partner Adaptive Biotechnologies are the latest pharma-biotech duo joining forces against the pandemic.

In our EuroBiotech roundup this week, AM-Pharma raises €23 million, Nordic Nanovector makes cuts and Neurimmune, Ethris plan COVID-19 trial.